Cartesian Therapeutics Announces New Employment Inducement Grants

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options to two new employees on February 2, 2026. The awards total 12,050 options with an exercise price of $6.79 per share, equal to the Nasdaq closing price that day.

The options vest 25% on February 2, 2027, then monthly over 36 months, fully vesting February 2, 2030, and carry a ten-year term. Grants were approved by the board and made under Nasdaq Rule 5635(c)(4) as inducements to employment.

News Market Reaction – RNAC

+2.06%

6 alerts

+2.06% News Effect

+$4M Valuation Impact

$189M Market Cap

0.4x Rel. Volume

On the day this news was published, RNAC gained 2.06%, reflecting a moderate positive market reaction. Our momentum scanner triggered 6 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $4M to the company's valuation, bringing the market cap to $189M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 12,050 shares Exercise price: $6.79 Initial vesting: 25% +5 more

8 metrics

Inducement options 12,050 shares Aggregate options granted to two new employees

Exercise price $6.79 Equal to Nasdaq closing price on February 2, 2026

Initial vesting 25% Vests on February 2, 2027

Monthly vesting tranches 36 installments After first anniversary, through February 2, 2030

Full vesting date February 2, 2030 Options fully vested by this date

Option term 10 years Expiration 10 years from grant date

Grant date February 2, 2026 Date options were granted

Rule reference Rule 5635(c)(4) Nasdaq Listing Rules provision used for inducement grants

Market Reality Check

Price: $6.25 Vol: Volume 71,012 vs 20-day a...

low vol

$6.25 Last Close

Volume Volume 71,012 vs 20-day average 115,500 (relative volume 0.61x) ahead of this HR update. low

Technical Shares at $6.79 were trading below the 200-day MA of $9.64, well under the $20 52-week high.

Peers on Argus

RNAC’s slight -0.59% move contrasted with mixed peers: CADL up 1.21%, OMER up 1....

1 Up

RNAC’s slight -0.59% move contrasted with mixed peers: CADL up 1.21%, OMER up 1.03%, while AVIR, DBVT, and NMRA were down between -0.5% and -3.55%. Momentum scans only flagged IVVD (+5.17%) separately.

Historical Context

5 past events · Latest: Jan 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 09	Outlook & pipeline	Positive	+1.0%	Outlined 2026 priorities and Descartes-08 Phase 3 AURORA and myositis plans.
Jan 06	Inducement grants	Neutral	+1.9%	Granted options for 7,350 shares to new employees under inducement plan.
Dec 18	Board appointment	Positive	-1.9%	Added experienced R&D leader Adrian Bot to the Board and S&T Committee.
Nov 13	Clinical data update	Positive	-4.6%	Reported strong Phase 2 Descartes-08 SLE efficacy and shifted focus to MG/myositis.
Nov 06	Earnings & update	Neutral	-1.6%	Q3 2025 results, cash runway to mid-2027, and multiple trial updates for Descartes-08.

Pattern Detected

Operational/clinical updates have often seen muted to slightly negative next-day moves, while routine governance and inducement items show small, mixed reactions.

Recent Company History

Over the last few months, RNAC has reported several milestones. On Nov 6, 2025, Q3 results highlighted $145.1M in cash and funding into mid-2027, followed by strong Phase 2 Descartes-08 SLE signals on Nov 13, 2025. A board appointment on Dec 18, 2025 and inducement grants on Jan 6, 2026 reflected ongoing organizational build-out. The Jan 9, 2026 outlook update emphasized Phase 3 AURORA enrollment and additional trials. Today’s new inducement grants fit this pattern of steady hiring-related equity awards alongside longer-term clinical execution.

Market Pulse Summary

This announcement details routine equity-based inducement awards tied to new hires, with options for...

Analysis

This announcement details routine equity-based inducement awards tied to new hires, with options for 12,050 shares at an exercise price of $6.79 vesting through 2030. It follows similar grants earlier in 2026, highlighting continued team expansion as RNAC advances Descartes-08 in Phase 3 and additional indications. In context of prior updates emphasizing cash runway into mid-2027 and multiple trials, this news mainly refines the picture of compensation and hiring rather than altering the company’s strategic trajectory.

Key Terms

cell therapy, exercise price, Nasdaq Listing Rules

3 terms

cell therapy medical

"a clinical-stage biotechnology company pioneering cell therapy for autoimmune"

Cell therapy uses living human or animal cells as the medicine: cells are collected, sometimes grown or altered, and then given to a patient to repair, replace, or boost damaged tissue or immune function. For investors, cell therapies can transform markets because they may offer one-time or highly effective treatments that command premium prices, but they also carry high development, manufacturing and regulatory costs and commercial risks, like building a custom factory rather than making a simple product.

exercise price financial

"options to purchase an aggregate of 12,050 shares ... with an exercise price of $6.79"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Nasdaq Listing Rules regulatory

"granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement"

Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.

AI-generated analysis. Not financial advice.

FREDERICK, Md., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On February 2, 2026, the Company issued to these employees options to purchase an aggregate of 12,050 shares of the Company’s common stock with an exercise price of $6.79, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on February 2, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on February 2, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis with plans to initiate a Phase 2 trial in myositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com

FAQ

What stock option grants did Cartesian Therapeutics (RNAC) announce on February 3, 2026?

Cartesian granted inducement options totaling 12,050 shares to two new employees. According to the company, options were issued on February 2, 2026 with a $6.79 exercise price equal to that day's Nasdaq close.

What are the vesting terms for the RNAC inducement options granted February 2, 2026?

The options vest 25% after one year, then monthly over three years, fully vesting on February 2, 2030. According to the company, that schedule follows the Amended and Restated 2018 Employment Inducement Incentive Award Plan.

What exercise price and term apply to the Cartesian Therapeutics (RNAC) inducement options?

The options carry an exercise price of $6.79 and a ten-year term from grant. According to the company, the $6.79 price matched the Nasdaq closing price on the grant date, February 2, 2026.

Under what authority were the RNAC inducement awards granted to new employees?

Grants were made under the company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and Nasdaq Rule 5635(c)(4). According to the company, the board approved the awards as inducements to employment.

Will the February 2, 2026 RNAC option grants immediately dilute existing shareholders?

The grants create potential future dilution if options are exercised, but no immediate share issuance occurred. According to the company, 12,050 options were issued with exercise at future conversion, subject to vesting and exercise.